SUMMARY
Non-typeable Haemophilus influenzae (NTHi) is a major cause of mucosal infections such as otitis media, sinusitis, conjunctivitis and exacerbations of chronic obstructive pulmonary disease. In some geographical regions, there is a strong causal relationship between NTHi and infections of the lower respiratory tract. Over the last 20 years, there has been a steady but constant increase in invasive NTHi disease globally with perinatal infants, young children and the elderly being most at risk. Individuals with underlying co-morbidities are most susceptible and infection is associated with significant mortality. Beta-lactamase production is the predominant mechanism of resistance. However, the emergence and spread of betalactamase negative ampicillin resistant strains across many regions of the world is of considerable concern, potentially necessitating alterations to current antibiotic treatment guidelines for community acquired upper and lower respiratory tract infection (LRTI) and potentially increasing morbidity associated with invasive NTHi infections. Standardised surveillance protocols and typing methodologies to monitor NTHi as an emerging pathogen across the world should be implemented. International scientific organisations need to take a lead in raising the profile of NTHi in the clinical and research communities, to document the pathobiology of this microbe as it responds to continued antibiotic and vaccination pressure. We believe that this lack of focus on NTHi is dangerous, as it facilitates the significant morbidity and increasing mortality associated with NTHi without encouraging the timely development of appropriate interventions. Here, we make the case for heightened surveillance of NTHi because: 1) data are emerging pointing to the increasing importance of NTHi as a pathogen in upper and lower respiratory tract infections, 11 2) there is evidence of an increase in invasive infections caused by NTHi, and 3) epidemiological data from several countries show an increase in the spread of non-beta -lactamase dependent resistance to beta-lactams in NTHi. In an attempt to raise the profile of NTHi, a website has been recently established: http://nthi-watch.griffith.edu.au/ to provide a single repository of knowledge on the pathogenesis, incidence and treatment of NTHi disease. The European Monitoring
Group on Meningococci (EMGM) recently expanded its scope to include H. influenzae and in recognition of the inclusion of H. influenzae, the acronym now stands for the European Monitoring Group on Meningitis.
HAEMOPHILUS SPECIES
Haemophilus spp are small fastidious Gram-negative cocco-bacilli that can be speciated by their requirements for X-Factor (haemin) and/or V-Factor (NAD) and other phenotypic characteristics. H. influenzae requires both X-Factor and V-Factor. Some strains of H.
influenzae are encapsulated and can be divided into 6 serotypes (a-f) based on their capsular polysaccharide. 12 NTHi strains cannot be serotyped by conventional type specific anti-serum agglutination. New molecular technologies have allowed a more accurate differentiation between typeable and non-typeable strains by detection of the cap locus which encodes the polysaccharide capsule. The cap locus consists of 3 regions. 15 Regions 1 and 3 are common to all capsular types and contain highly conserved genes necessary for processing and transport of capsular material to the cell surface.. Region 2 contains typespecific genes involved in capsule biosynthesis. A polymerase chain reaction (PCR)-based method to detect the region 1 bexB gene may be used as a proxy for the capsule locus, 19 and can distinguish true NTHi from strains that contain a complete or partial capsule locus.
Strains with a partial capsule locus are unable to export polysaccharide to the cell surface and therefore appear to be NTHi as they are non-serotypeable by conventional means.
Serological capsular typing is prone to misinterpretation. Satola et al. 20 reported discrepancies between serological typing and PCR-based capsular typing for 17.5% of 360 43 , which is also likely to increase the incidence of NTHi conjunctivitis. Surveillance studies should be undertaken to determine the impact of pneumococcal vaccination on COS prevalence.
Bacterial sinusitis is a common complication of childhood viral upper respiratory tract infection, and the fifth most common diagnosis for which antibiotics are prescribed in children in the USA. 71 In children with chronic sinusitis, S. pneumoniae and H. influenzae predominate. 76 The introduction of Prevenar™ in the USA saw an increase in the proportion of nasopharyngeal NTHi colonisation in children with sinusitis, from 25% to 41% from 1997 to 2005. 77 Exacerbations of COPD, persistent bacterial bronchitis and cystic fibrosis: COPD is one of the leading causes of death globally with disease burden expected to increase significantly. 78 There is now extensive evidence demonstrating that NTHi colonisation of the airways is a major cause of airway inflammation and tissue damage, particularly during acute exacerbations. 79 Firstly, NTHi is a major pathogen colonising damaged airways in subjects with COPD, 5 and when present, predominates. 6 There is evidence that acute exacerbations of COPD can be attributed to the acquisition of 'exacerbation' isolates of NTHi. 81 During acute exacerbations, NTHi detection in bronchus brush biopsies increases from 33% in subjects with stable COPD to 87% in subjects with exacerbations. 81 Secondly, oral immunisation with an enteric killed whole-cell vaccine of subjects with severe COPD significantly reduces the number and severity of acute exacerbations. 83, 84 Thirdly, the detection of specific NTHi IgE antibodies in subjects with COPD suggests that an IgEmediated hypersensitivity to NTHi antigens contributes to the reversible airway obstruction and bronchial hyper-reactivity often observed in these subjects. 85 Persistent bacterial bronchitis (PBB) is an underdiagnosed clinical presentation which is most common in <5 year-olds and is characterised by chronic cough. 86, 87 Culture of cough swabs obtained from children with PBB were positive for H. influenzae from 81% of samples tested, 88 and most of these were NTHi. Broncho-alveolar lavage (BAL) samples from children with PBB have confirmed NTHi as the major causative agent in Greece and the United Kingdom (UK). 89 Importantly, a recent Australian study of indigenous children with bronchiectasis confirmed by molecular typing that the majority of phenotypic NTHi isolates from both BAL and nasopharynx were PCR-positive for protein D and, therefore, not H. has also been isolated from routine urine and urethral cultures in adult males 154 , though the significance is unknown.
After the neonatal period, the incidence of NTHi invasive disease is low and relatively stable.
In countries with established Hib vaccination programmes, the median age at onset of invasive H. influenzae disease has now shifted from early childhood to late adulthood because most invasive infections are now due to NTHi, which has a median age at disease onset of around 60 years. 118 Most invasive NTHi cases in children (40% to 70%) and adults (60% to 80%) occur in individuals with underlying co-morbidities, particularly chronic respiratory disease and impaired immunity, 137, 141, 155-159 although a recent Swedish study reported co-morbidity in only 38% of cases. 120 Interestingly, this study found disorders of B cell immunity such as chronic lymphatic leukaemia and multiple myeloma to be particularly common among patients with invasive NTHi, suggesting an important role for humoral immunity. 120 The authors also speculated that the age-related decline in B-cell function may also explain the increasing incidence of invasive NTHi with age. 120 The clinical presentation of invasive NTHi disease varies with age. The vast majority of neonatal cases develop septicaemia without a focus. Clinical presentation with meningitis is more common in older infants and children and then declines with age. The most common clinical presentation overall is pneumonia, which increases with age and occurs mainly in older adults who often have underlying respiratory tract co-morbidities. 124-, 158 Other clinical presentations such as epiglottitis (characteristic of invasive Hib disease), bone and joint infections, as well as skin and soft tissue infections, have been reported but are uncommon, although cholecystitis appears to be a particular feature of invasive NTHi disease. [124] [125] [126] 158 It is important to emphasise that, as in neonates, NTHi can cause serious morbidity in older age groups. The aforementioned Swedish study, for example, reported that 48% of 101
invasive NTHi cases had severe sepsis or septic shock and 20% required intensive care. subsequently succumb to their underlying illness. In the Swedish study, for example, the 28-day CFR was 8%, but 1-year CFR increased to 29%. 120 
DEVELOPMENT OF RESISTANCE IN NTHI
In H. influenzae and NTHi, beta-lactamase production is still the dominant resistance mechanism against beta-lactams. The beta-lactamase prevalence in NTHi differs widely worldwide. Over the last decade, studies have reported percentages of beta-lactamasepositive NTHi between 10% and 25% in most countries (South-Africa, Europe , USA, Canada, Central and South-America). [161] [162] [163] [164] [165] [166] In some regions, beta-lactamase -positive NTHi represent up to 55% of NTHi (Taiwan, Vietnam, Japan, South-Korea). [167] [168] [169] [170] [171] The beta-lactamase found in H. influenzae is usually a plasmid-encoded class A serine beta-lactamase; most often a TEM-1, rarely ROB-1, although regional differences exist. 172 These BLNAR strains were isolated primarily from cases of conjunctivitis. Reports also indicate higher and increasing levels of BLNAI/R in Poland, France and Portugal, with increasing prevalence of genotype III-like strains. [188] [189] [190] [191] [192] In Sweden, a significant increase in beta-lactam-resistant invasive H. influenzae mainly due to beta-lactamase-negative isolates was observed from 2007 onwards. One cluster of BLNAR genotype IIb isolates was identified and it included isolates from all geographical areas. 193 A preliminary report also suggests and increase in BLNAI in Canada starting in 2000. 194, 195 For many parts of the world, little or no data on BLNAI/R are available. Likely because regular surveillance of NTHi is lacking or microbiological work-up of NTHI is limited to a nitrocefin test for beta-lactamase production. In addition, currently accepted resistance breakpoints of >1 µg/ml or >2 µg/ml as determined by the Clinical and laboratory Standards Institute (CLSI) and EUCAST, respectively, for beta-lactamase negative H. influenzae probably led to an underestimation of the prevalence of BLNAR. This is also the case for BLPACR; the CLSI breakpoint of ≥8 µg/ml for co-amoxyclav is likely to miss many strains in which the MIC value is increased to only 2 µg/ml. The EUCAST breakpoint of >1 µg/ml is more likely to pick up these strains.
The further spread of non-beta-lactamase dependent beta-lactam resistant strains, and in particular the genotype III BLNAR and BPLACR, has important implications for treatment.
This is not only the case for strains with ampicillin MIC values of 4 µg/ml or more. Clinical data suggest that current dosages of aminopenicillins will not guarantee clinical success in certain types of infections, such as chronic or recurrent OM, if MIC values are 1 or 2 µg/ml.
Changing to other classes of antibiotics offers only a partial solution. H. influenzae is intrinsically resistant to macrolide-lincosamide-streptograminB agents including ketolides. [196] [197] [198] Even for strains with low macrolide MIC values, the outcome in AOM for treatment with macrolides has been shown not to differ from placebo. 199 H. influenzae is rarely resistant to quinolones but their use in children is not yet approved. It is also commonly accepted that the use of quinolones in paediatric respiratory infections would significantly enhance selective pressure for the emergence and selection of resistant S.
pneumoniae and H. influenzae. In conclusion, a further spread of these BLNAR and BLPACR could make it necessary to change the current treatment guidelines for community-acquired upper and lower respiratory tract infections.
GENERAL CONCLUSION
Improved surveillance of H. influenzae is needed to follow the trends described here. 2 Usually associated with underlying co-morbidity (40-70% in children; 60-80% in adults)
Epiglottis and bone, joint, skin and soft tissue infections have been reported but at a low incidence. [124] [125] [126] 
